Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

AbCellera Reports Full Year 2025 Business Results

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Full Year 2025 Business Results.

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of VMS Due to Menopause.

AbCellera and Bruker Reach Global Settlement of Patent Litigation

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera and Bruker Reach Global Settlement of Patent Litigation.

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Appoints Dr. Stephen Quake to its Board of Directors.